A Phase I, Partially-randomised, Partially Double-blinded, Safety, Tolerability and Pharmacokinetic Study of ABY-035 in Healthy Subjects and Psoriasis Patients
Phase of Trial: Phase I
Latest Information Update: 14 Oct 2016
At a glance
- Drugs Interleukin-17 inhibitors (Primary) ; Interleukin-17 inhibitors (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; First in man
- Sponsors Affibody
- 07 Jun 2017 Biomarkers information updated
- 07 Oct 2016 Time frame of primary endpoint has been changed from Follow-up visit (Day 95) to Follow-up visit (Day 141). number of treatment arms and patients number also increases.
- 07 Oct 2016 Planned number of patients changed from 58 to 64.